Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The GM1 Gangliosidosis Market?

The market for gm1 gangliosidosis has experienced swift expansion in the recent past. The market will amplify from $0.51 billion in 2024 to $0.57 billion in 2025, representing a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this progression in the historic period comprise an escalating number of gm1 gangliosidosis patients, the burgeoning focus on the gm1 gangliosidosis field, the increasing awareness of rare diseases, rising trend of research focused on the patient, and an amplified emphasis on early intervention.

Anticipated to experience swift expansion in the coming years, the gm1 gangliosidosis market is projected to escalate to a worth of $0.87 billion by 2029, fostering a compound annual growth rate (CAGR) of 11.0%. The predicted growth across the forecast period is a culmination of factors such as a heightened number of gm1 gangliosidosis instances, an increasing prevalence of lysosomal storage disorder, a surge in clinical trials, a growing emphasis on gene therapy and editing, an emerging trend toward personalized and precision medicine, and a growing predisposition for genetic screening programs. Significant trends anticipated during the forecast period are the progressive strides made in gene-editing technologies, the incorporation of technology into healthcare, advancements in diagnostic methodologies, enhanced formulations, and forward leaps in genetic therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

What Core Drivers Are Expected To Influence The GM1 Gangliosidosis Market?

The GM1 gangliosidosis market is predicted to thrive owing to the escalating application of gene therapy. This therapeutic approach involves the modification or replacement of genes in an individual’s cells to manage or prevent illnesses. The widened usage of gene therapy is fostered by genetic research advancements, improved patient outcomes for conditions previously deemed untreatable, and increasing regulatory backing for innovative treatments. Treating GM1 gangliosidosis with gene therapy entails the delivery of a functional copy of the flawed gene (GLB1) to the patient’s cells, which helps restore ß-galactosidase enzyme activity and reduce harmful substrate accumulation. For example, the American Society of Gene & Cell Therapy, a non-profit medical and scientific organization based in the US, indicated that the phase III gene therapy clinical trials increased by 10% in the fourth quarter of 2024 – the first growth seen since the third quarter of 2022. Therefore, the growing application of gene therapy is bolstering the expansion of the GM1 gangliosidosis market.

What Are The Main Segment Classifications In The GM1 Gangliosidosis Market?

The gm1 gangliosidosismarket covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis; Type 2 GMT Gangliosidosis; Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants; Bone Marrow Transplantation; Cord-Blood Hematopoietic Stem-Cell Transplantation; Enzyme Replacement; Gene Therapy

3) By End-User: Research Institutes; Hospitals; Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset; Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset; Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset; Atypical Adult Onset

How Are Industry Trends Steering The Expansion Of The GM1 Gangliosidosis Market?

Companies in the GM1 gangliosidosis market are strengthening their market position through strategic alliances that help accelerate gene therapy development. These partnerships pool resources and expertise for faster research and commercialization. In October 2024, U.S.-based GEMMA Biotherapeutics Inc. joined forces with Brazil’s Oswaldo Cruz Foundation (Fiocruz) to develop gene therapies for rare conditions like GM1 gangliosidosis. Fiocruz is providing up to $100 million in funding for clinical trials and manufacturing, aiming to make these treatments accessible via Brazil’s public health system. The collaboration also emphasizes tech transfer to broaden access beyond high-income regions.

Which Companies Are Contributing Significantly To The GM1 Gangliosidosis Market Growth?

Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Region Holds The Greatest Opportunity For GM1 Gangliosidosis Market Expansion?

North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Epigenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

Direct To Consumer Dtc Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-genetic-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model